RecruitingPhase 2NCT07029581
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Sponsor
ACADIA Pharmaceuticals Inc.
Enrollment
180 participants
Start Date
Aug 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Eligibility
Min Age: 55 YearsMax Age: 84 Years
Inclusion Criteria6
- Male or female ≥55 years to <85 years of age at the Screening visit living in the community or, if permitted by local regulations, in an institutionalized setting
- Can provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met:
- The subject's LAR must provide written informed consent.
- The subject must provide written (if capable) informed assent per local regulations.
- Meets either the clinical criteria for Parkinson's disease with dementia as defined by the Movement Disorder Society's Task Force or the revised clinical criteria for probable dementia with Lewy bodies (DLB) by consensus criteria (Fourth consensus report of the DLB Consortium).
- Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association
Exclusion Criteria5
- Is in hospice, is receiving end-of-life palliative care, or is bedridden
- Has psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition (e.g. schizophrenia, bipolar disorder, delusional disorder) other than dementia
- Is actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)
- Has a history or current evidence of a serious and/or significant unstable cardiovascular, respiratory, endocrine, gastrointestinal, renal, hepatic, hematologic, immunologic, genitourinary, psychiatric or neurologic (including stroke, chronic seizures, or clinically significant head injury) abnormality or disease or other medical disorder, including cancer or malignancies that could interfere with subject's ability to complete the study or comply with study procedures
- Has other clinically significant CNS abnormalities that are most likely contributing to the dementia or findings on MRI or CT
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGACP-204
Provided as 1 capsule, to be taken orally once daily
DRUGPlacebo
Provided as 1 capsule, to be taken orally once daily
Locations(54)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029581